Eltrombopag olamine

CAS: 496775-62-3

Ref. 3D-FD157443

Produktinformation

• Name: Eltrombopag olamine
• Synonyme: 2-aminoethanol3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid, (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-, compound with 2-aminoethanol (1:2), 3'-((2Z)-2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)diazanyl)-2'-hydroxybiphenyl-3-carboxylic acid compound with 2-aminoethanol (1:2), Eltrombopag Olamine [USAN], Eltrombopag diethanolamine salt, Promacta, Revolade, Sb 497115Gr, Sb-497115-Gr, Unii-4U07F515Lg, [1,1′-Biphenyl]-3-carboxylic acid, 3′-[(2Z)-2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2′-hydroxy-, compd. with 2-aminoethanol (1:2), [1,1′-Biphenyl]-3-carboxylic acid, 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-, compd. with 2-aminoethanol (1:2)

Beschreibung

Eltrombopag olamine is an orally active drug that belongs to the class of thiazolidinones. It has been used for the treatment of thrombocytopenia in patients with chronic liver disease and myelodysplastic syndrome. Eltrombopag olamine inhibits platelet aggregation by binding to glycoprotein IIb/IIIa receptors on the surface of platelets. The drug is a prodrug that is metabolized in vivo to its active form, eltrombopag. This conversion is catalysed by CYP3A4 and CYP2D6 enzymes and can be inhibited by drugs that inhibit these enzymes, such as trifluoroacetic acid and hydroxyl group-containing compounds. Eltrombopag olamine binds to erythrocytes, which may be due to its ability to form intramolecular hydrogen bonds with nitrogen atoms. The synthesis of elt

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 564.63 g/mol
• Formel: C₂₅H₂₂N₄O₄•(C₂H₇NO)₂
• Reinheit: Min. 95%
• Farbe/Form: Powder